Weslaco Research and Clinical Trials
Texas Oncology in Weslaco participates in a wide range of groundbreaking research that is paving the way for new breakthroughs in cancer care. As a Texas Oncology patient, you may be able to take part in these innovative clinical trials.
Anal Cancer
DETECT-ASCEND 2 Plasma Based Test
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test
Phase: I
Biliary Cancer
Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract
A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002) Read Moreabout Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract
Phase: II/III
STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)
Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011) Read Moreabout STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)
Phase: II/III
Bladder Cancer
DETECT-ASCEND 2 Plasma Based Test
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test
Phase: I
Breast Cancer
SCRI: BRE 409: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03)
A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001) Read Moreabout SCRI: BRE 409: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03)
Phase: III
Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA)
A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH EXEMESTANE PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171) Read Moreabout Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA)
Phase: III
DETECT-ASCEND 2 Plasma Based Test
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test
Phase: I
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH) Read Moreabout Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
Phase: III
Carcinoid
Cervical Cancer
DETECT-ASCEND 2 Plasma Based Test
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test
Phase: I
Colon Cancer
DETECT-ASCEND 2 Plasma Based Test
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test
Phase: I
Endometrial Cancer
DETECT-ASCEND 2 Plasma Based Test
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test
Phase: I
Esophageal Cancer
DETECT-ASCEND 2 Plasma Based Test
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test
Phase: I
Fallopian Tube Cancer
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066) Read Moreabout STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
Phase: II
Gall Bladder Cancer
Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract
A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002) Read Moreabout Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract
Phase: II/III
Gastric Cancer
Head and Neck Cancer
STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC
A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01) Read Moreabout STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC
Phase: I
DETECT-ASCEND 2 Plasma Based Test
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test
Phase: I
Hematologic
Kidney Cancer
DETECT-ASCEND 2 Plasma Based Test
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test
Phase: I
Leukemia
STAR: Zanu in Acala intolerant B-Cell
A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215) Read Moreabout STAR: Zanu in Acala intolerant B-Cell
Phase: II
Liver Cancer
DETECT-ASCEND 2 Plasma Based Test
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test
Phase: I
Lung Cancer
STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR
(FURMO-004) A Global Phase 3 Randomized Multicenter Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations Read Moreabout STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR
Phase: III
STAR PH3 EGFRm stage2/3b NSCLC
A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001) Read Moreabout STAR PH3 EGFRm stage2/3b NSCLC
Phase: III
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777) Read Moreabout STAR: PH1/3 Biomarker unresectable stg3 NSCLC
Phase: III
STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX) Read Moreabout STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
Phase: III
STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)
Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011) Read Moreabout STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)
Phase: II/III
DETECT-ASCEND 2 Plasma Based Test
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test
Phase: I
Lymphomas
Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph
A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302) Read Moreabout Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph
Phase: I
STAR: Zanu in Acala intolerant B-Cell
A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215) Read Moreabout STAR: Zanu in Acala intolerant B-Cell
Phase: II
Ph3 LOXO-305 vs PC of BTK in MCL
A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019) Read Moreabout Ph3 LOXO-305 vs PC of BTK in MCL
Phase: III
Melanoma
Myelodysplastic Syndrome
Myelomas
Neuroendocrine Tumors
Ph3 CAM2029 Lanreo ATG GEP-NET
A RANDOMIZED MULTI-CENTER OPEN-LABEL ACTIVE-CONTROLLED PHASE 3 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF OCTREOTIDE SUBCUTANEOUS DEPOT (CAM2029) VERSUS OCTREOTIDE LAR OR LANREOTIDE ATG IN PATIENTS WITH GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (HS-19-657) Read Moreabout Ph3 CAM2029 Lanreo ATG GEP-NET
Phase: III
Ovarian Cancer
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066) Read Moreabout STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
Phase: II
DETECT-ASCEND 2 Plasma Based Test
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test
Phase: I
Pancreatic Cancer
Ph3 CAM2029 Lanreo ATG GEP-NET
A RANDOMIZED MULTI-CENTER OPEN-LABEL ACTIVE-CONTROLLED PHASE 3 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF OCTREOTIDE SUBCUTANEOUS DEPOT (CAM2029) VERSUS OCTREOTIDE LAR OR LANREOTIDE ATG IN PATIENTS WITH GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (HS-19-657) Read Moreabout Ph3 CAM2029 Lanreo ATG GEP-NET
Phase: III
STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)
Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011) Read Moreabout STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)
Phase: II/III
DETECT-ASCEND 2 Plasma Based Test
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test
Phase: I
Peritoneal Cancer
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066) Read Moreabout STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
Phase: II
Prostate Cancer
STAR PH3 Abi+/-Capi mHSPC CAPItello-281
A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001 Read Moreabout STAR PH3 Abi+/-Capi mHSPC CAPItello-281
Phase: III
DETECT-ASCEND 2 Plasma Based Test
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test
Phase: I
Rectal Cancer
Renal Cancer
DETECT-ASCEND 2 Plasma Based Test
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test
Phase: I
Skin Cancer
Solid Tumors
STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes
A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007) Read Moreabout STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes
Phase: II
DETECT-ASCEND 2 Plasma Based Test
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test
Phase: I
Testicular Cancer
DETECT-ASCEND 2 Plasma Based Test
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test
Phase: I
Thyroid Cancer
DETECT-ASCEND 2 Plasma Based Test
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test
Phase: I
Urothelial Cancer
STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)
Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011) Read Moreabout STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)
Phase: II/III
Uterine Cancer
DETECT-ASCEND 2 Plasma Based Test
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test
Phase: I
Vulvar Cancer
DETECT-ASCEND 2 Plasma Based Test
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test
Phase: I